Prostate-specific membrane antigen targeting positron emission tomography (PSMA-PET) in prostate cancer: PSMA-RADS classification and PROMISE criterias

被引：0

作者：

Robin, P. ^{[1
,2
,5
]}

Palard-Novello, X. ^{[3
,4
]}

Bailly, C.

机构：

[1] Ctr Hosp Univ Brest, Serv Med Nucl, 2 Ave Foch, F-29269 Brest, France

[2] Univ Brest, CHU Brest, UMR 1304, Inserm, Brest, France

[3] Univ Rennes, CLCC Eugene Marquis, INSERM, LTSI UMR 1099, Ave Bataille Flandres Dunkerque, F-35042 Rennes, France

[4] Ctr Hosp Univ Nantes, Serv Med Nucl, Nantes, France

[5] Univ Brest, Ctr Hosp & Univ Brest, Inserm, UMR 1304,CHRU Brest,GETBO,Serv Med Nucl, 2 Ave Foch, F-29609 Brest, France

来源：

MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE | 2023年 / 47卷 / 05期

关键词：

Positron emission tomography; Prostate specific membrane antigen; receptor; Prostate cancer; Classifications; VERSION; PEARLS; EANM;

D O I：

10.1016/j.mednuc.2023.07.005

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Prostate-specific membrane antigen targeting positron emission tomography (PSMA-PET) is nowadays widely used for the management of patients with prostate cancer during natural history of the disease. PSMA is not specific to prostate tissue, many benign and malignant diseases unrelated to prostate cancer are frequently found on PSMA-PET examinations, leading to false positives results and potentially to inadequate patient management. Various interpretation criteria have been proposed within classifications in order to standardize and homogenize PSMA-PET interpretation. This article describes, on the one hand the PSMA-RADS classification, and on the other hand the PROMISE criteria. (c) 2023 Elsevier Masson SAS. All rights reserved.

引用

页码：270 / 275

页数：6

共 15 条

[1] Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
Eiber, Matthias
Herrmann, Ken
Calais, Jeremie
Hadaschik, Boris
Giesel, Frederik L.
Hartenbach, Markus
Hope, Thomas
Reiter, Robert
Maurer, Tobias
Weber, Wolfgang A.
Fendler, Wolfgang P.
[J]. JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (03) : 469 - 478
[2] False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial
Fendler, Wolfgang P.
Calais, Jeremie
Eiber, Matthias
Simko, Jeffrey P.
Kurhanewicz, John
Delos Santos, Romelyn
Feng, Felix Y.
Reiter, Robert E.
Rettig, Matthew B.
Nickols, Nicholas G.
Kishan, Amar U.
Slavik, Roger
Carroll, Peter R.
Lawhn-Heath, Courtney
Herrmann, Ken
Czernin, Johannes
Hope, Thomas A.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (02) : 501 - 508
[3] 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
Fendler, Wolfgang P.
Eiber, Matthias
Beheshti, Mohsen
Bomanji, Jamshed
Ceci, Francesco
Cho, Steven
Giesel, Frederik
Haberkorn, Uwe
Hope, Thomas A.
Kopka, Klaus
Krause, Bernd J.
Mottaghy, Felix M.
Schoder, Heiko
Sunderland, John
Wan, Simon
Wester, Hans-Juergen
Fanti, Stefano
Herrmann, Ken
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (06) : 1014 - 1024
[4] 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer
Fendler, Wolfgang P.
Schmidt, Dorothea F.
Wenter, Vera
Thierfelder, Kolja M.
Zach, Christian
Stief, Christian
Bartenstein, Peter
Kirchner, Thomas
Gildehaus, Franz J.
Gratzke, Christian
Faber, Claudius
[J]. JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (11) : 1720 - 1725
[5] Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls
Foley, R. W.
Redman, S. L.
Graham, R. N.
Loughborough, W. W.
Little, D.
[J]. CLINICAL RADIOLOGY, 2020, 75 (12) : 903 - 913
[6] F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
Giesel, Frederik L.
Hadaschik, B.
Cardinale, J.
Radtke, J.
Vinsensia, M.
Lehnert, W.
Kesch, C.
Tolstov, Y.
Singer, S.
Grabe, N.
Duensing, S.
Schaefer, M.
Neels, O. C.
Mier, W.
Haberkorn, U.
Kopka, K.
Kratochwil, C.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (04) : 678 - 688
[7] 68Ga-PSMA PET/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls
Keidar, Zohar
Gill, Ronit
Goshen, Elinor
Israel, Ora
Davidson, Tima
Morgulis, Maryna
Pirmisashvili, Natalia
Ben-Haim, Simona
[J]. CANCER IMAGING, 2018, 18
[8] EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Mottet, Nicolas
van den Bergh, Roderick C. N.
Briers, Erik
Van den Broeck, Thomas
Cumberbatch, Marcus G.
De Santis, Maria
Fanti, Stefano
Fossati, Nicola
Gandaglia, Giorgio
Gillessen, Silke
Grivas, Nikos
Grummet, Jeremy
Henry, Ann M.
van der Kwast, Theodorus H.
Lam, Thomas B.
Lardas, Michael
Liew, Matthew
Mason, Malcolm D.
Moris, Lisa
Oprea-Lager, Daniela E.
van der Poel, Henk G.
Rouviere, Olivier
Schoots, Ivo G.
Tilki, Derya
Wiegel, Thomas
Willemse, Peter-Paul M.
Cornford, Philip
[J]. EUROPEAN UROLOGY, 2021, 79 (02) : 243 - 262
[9] Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy
Rauscher, Isabel
Kroenke, Markus
Koenig, Michael
Gafita, Andrei
Maurer, Tobias
Horn, Thomas
Schiller, Kilian
Weber, Wolfgang
Eiber, Matthias
[J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (01) : 51 - 57
[10] PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies
Rowe, Steven P.
Pienta, Kenneth J.
Pomper, Martin G.
Gorin, Michael A.
[J]. EUROPEAN UROLOGY, 2018, 73 (04) : 485 - 487

← 1 2 →